Clinical Trials
49 trialsCOBRA
Istituto Oncologico Veneto IRCCS
Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC
CHA University
International Multicentric Study ARON-1
Hospital of Macerata
HCC
CHA University
Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis
University of California, San Diego
KOSMOSII
Seoul National University Bundang Hospital
CCGLC-001
Tongji Hospital
Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Multicenter Retrospective Study on Optimizing Combination Immunotherapy Strategies in MSS/MSI-L/pMMR Advanced Colorectal Cancer
Central South University
OVNI-B
Centre Hospitalier Universitaire de NÄ«mes
A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer
Sun Yat-sen University
CCGLC-008
Tongji Hospital
Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM
Zhongda Hospital
89Zr-Bevacizumab PET/CT Imaging in NF2 Patients
Leiden University Medical Center
HCC
CHA University
Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma
Sun Yat-sen University
Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer
Hunan Province Tumor Hospital
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC
Hunan Cancer Hospital
Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis
Fudan University
Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer
Hunan Cancer Hospital
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
COMET
UNICANCER
Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI
Massachusetts General Hospital
a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors
The University of Hong Kong-Shenzhen Hospital
Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study
Fudan University
The Effects of Preoperative Bevacizumab on Perioperative Complications
Second Affiliated Hospital, School of Medicine, Zhejiang University
BELLA
Guangdong Association of Clinical Trials
ROBOT
Peking University People's Hospital
ARBITRATION
National Cancer Institute, Naples
Psychometric Properties of the EORTC QLQ-LC29
University Hospital Regensburg
Breast Cancer Treatment Based on Organ-like Culture
Xijing Hospital
AVOCETTE
University Hospital, Caen
REBECA
Yonsei University
CIRCUS
Azienda Ospedaliero, Universitaria Pisana
Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer
Hoosier Cancer Research Network
COBEQOL
Centre Hospitalier Universitaire de Besancon
ENCOURAGE
ARCAGY/ GINECO GROUP
BevaRet
Technische Universität Dresden
An Observational Study of Bevacizumab in Chinese Patients With Metastatic Colorectal Cancer
Peking University
Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients
Medical University Innsbruck
Hypertension in Breast Cancer Patients Receiving Bevacizumab
Dana-Farber Cancer Institute
Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer
Sun Yat-sen University
Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients
University of Rome Tor Vergata
VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer
Huazhong University of Science and Technology
ANGIOMET
Spanish Lung Cancer Group
Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project
Stanford University
BIBC
Xijing Hospital
A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer
King Faisal Specialist Hospital & Research Center
First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer
Azienda Ospedaliero, Universitaria Pisana